Correction to: BMC Cancer
https://doi.org/10.1186/s12885-016-2196-2
Following publication of the original article [1], the authors reported an error in Fig. 6c and in the figure legends for Fig. 5c and Fig. 6c.
In Fig. 6c there has been a duplication of the western blot panel for p130Cas resulting in that the same panel is shown for Smad2/3 and p130Cas. This has now been changed in the figure and the correct panel for Smad2/3 has now been included. Fig. 6 is supplied below.
In figure legend 5c the text:
c, upper panel, western blot analysis of whole cell extracts from HC11 and HC11FoxF1 cells probed with phosphospecific p130Cas antibody, stripped and re-probed with p130Cas and α-tubulin antibodies.
has been corrected to:
c, upper panel, western blot analysis of whole cell extracts from HC11 and HC11FoxF1 cells probed with either phosphospecific p130Cas antibody or p130Cas and α-tubulin antibodies.
In figure legend 6c the text:
c, upper panel, western blot analysis of HC11FoxF1 cells untreated or treated with FAK inhibitor (FAK inhibitor 14, Santa Cruz) 20 μM for 1 h. The effect of the FAK inhibitor was confirmed by analyzing FAK phosphorylation levels at Y396 (data not shown). Whole cell extracts were probed with FAK-pY576 antibody, stripped and re-probed FAK and α-tubulin antibodies. Nuclear extracts were probed with phosphospecific Smad2 and HDAC-1 antibodies. Whole cell extracts were probed with phosphospecific p130Cas and Smad2/3 antibodies, stripped and re-probed with p130Cas and α-tubulin antibodies.
has been corrected to:
c, upper panel, western blot analysis of HC11FoxF1 cells untreated or treated with FAK inhibitor (FAK inhibitor 14, Santa Cruz) 20 μM for 1 h. The effect of the FAK inhibitor was confirmed by analyzing FAK phosphorylation levels at Y396 (data not shown). Whole cell extracts were probed with either FAK-pY576 antibody or FAK and α-tubulin antibodies. Nuclear extracts were probed with phosphospecific Smad2 and HDAC-1 antibodies. Whole cell extracts were probed with phosphospecific p130Cas and Smad2/3 antibodies, stripped and re-probed with p130Cas and α-tubulin antibodies.
Reference
- 1.Nilsson G, Kannius-Janson M. Forkhead Box F1 promotes breast cancer cell migration by upregulating lysyl oxidase and suppressing Smad2/3 signaling. BMC Cancer. 2016;16:142. doi: 10.1186/s12885-016-2196-2. [DOI] [PMC free article] [PubMed] [Google Scholar]